MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. Its CEO and CFO discuss with In Vivo the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.
